Well said. There's many dependencies here. is one of 1 day dose >= dapto Financial quality of partnership deal Uplisting BOD profiles Big funds able to buy in
Then you have the new investors that spot the higher % SP change on financial news so they buy, and then they study/read for a month about their new investment and other drugs in its pipeline and trial stages and potential and depending on this they possibly buy more either selling other stocks and/or using free cash....etc...AND eventually a MARKET cap of the company is examined to determine is this fair value considering potential and uniqueness benefit of these drugs considering where we are in the game with each of them right at this time.
Market Data 
Markets 
AI
